ReviewCurrent pharmaceutical design2026
Effect of Amino Acid Peritoneal Dialysis Solution on Low Protein Treatment in Peritoneal Dialysis Patients.
Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal dialysis (PD) is one of the commonly used treatments for patients with end-stage renal disease (ESRD). Despite technological advances, mortality rates in patients with PD remain high. Nutritional status is an important factor affecting the prognosis of PD patients; low protein, as a complication of PD patients after dialysis, may lead to malnutrition, oedema of both lower limbs or whole body, decreased immunity, aggravation of the condition and other adverse consequences. It will also increase the mortality rate of patients and increase the incidence of cardiovascular and cerebrovascular diseases, which is considered to be the main limiting factor of PD. As a substitute for traditional glucose dialysate, Amino Acid Deritoneal Dialysate (AAD) stimulates protein synthesis by increasing amino acid availability in PD patients and inducing hyperamino acidemia due to its sugar-free and good biocompatibility. Based on literature retrieved from Pub- Med, Web of Science and Scopus, we found that AAD can not only effectively improve the nutritional status of PD patients, but also effectively alleviate the complications of low protein caused by traditional dialysate. Although AAD has shown promise in the treatment of low-protein patients, further randomized controlled trials are needed to verify its long-term efficacy and safety. AAD provides a new treatment option for patients with low protein, which has vital clinical significance.
Indexed as
Identifiers
41487009What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.